ISS initiates DKK 2.5 billion share buyback programme Company Announcement Copenhagen, 19 February 2026No. 10/2026 ISS initiates DKK 2.5 billion share buyback programme ISS A/S (“ISS”), a leading workplace experience and facility management company, today announces that the Board of Directors has decided to initiate a share buyback programme, under which ISS will buy back own shares for a maximum consideration of DKK 2.5 billion over a 12-month period from 19 February 2026 to 22 February 2027 at the latest, both days inclusive. Through the share buyback programme, ISS wishes to redistri...
Robust financial performance in 2025 in line with expectations. ISS initiates a new share buyback programme of DKK 2.5 billion Company announcement Copenhagen, 19 February 2026 No. 9/2026 Robust financial performance in 2025 in line with expectations. ISS initiates a new share buyback programme of DKK 2.5 billion ISS announces 2025 financial results and 2026 outlookHighlightsFinancial performance update Organic growth was 4.3% in 2025 (2024: 6.3%), and 4.4% in H2 2025 (H2 2024: 6.6%), mainly driven by price increases implemented across the Group, positive volume growth partly offset...
Valneva meldet vorläufige ungeprüfte Umsätze und liquide Mittel für 2025; gibt einen Ausblick für 2026 Gesamtumsatz von 174,7 Millionen Euro im Rahmen der Prognose, davon 157,9 Millionen Euro aus Produktumsatz Starke Liquiditätsposition zum Jahresende in Höhe von 109,7 Millionen Euro, mit verbesserter finanzieller Flexibilität nach erfolgreicher Umschuldung 2026 könnte ein Jahr des Wandels werden, da in der ersten Jahreshälfte Daten zur Phase 3 der Lyme-Borreliose-Studie erwartet werden Der Vertrag des Chief Executive Officers wurde um weitere drei Jahre verlängert, wodurch die Kontinuität...
Valneva Reports Preliminary Unaudited 2025 Revenue and Cash and Provides 2026 Outlook Total Revenues of €174.7 million in line with guidance, including €157.9 million in product sales Strong year-end cash position of €109.7 million, with enhanced financial flexibility following successful debt refinancing 2026 to be a potentially transformational year with Phase 3 Lyme disease data expected in the first half of the yearChief Executive Officer’s contract renewed for a further three-year term, ensuring continuity in leadership Lyon (France), February 19, 2026 – (Nasdaq: VALN; Euronext Paris...
Valneva publie son chiffre d’affaires et sa trésorerie non audités pour l’exercice 2025 et fournit ses prévisions pour l’exercice 2026 Chiffre d’affaires de 174,7millions d’euros en ligne avec les prévisions, dont 157,9 millions d’euros de ventes de vaccinsSolide position de trésorerie de 109,7 millions d’euros à fin 2025 et flexibilité financière renforcée suite au refinancement réussi de la dette 2026 pourrait être une année transformatrice pour Valneva, avec des données de Phase 3 sur le vaccin Lyme attendues au premier semestre.Mandat du Directeur Général de Valneva renouvelé pour une...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.